3.92.96.247
dgid:
enl:
npi:0
-Advertisement-
-Advertisement-

Genetic and Congenital

Rett syndrome phase 3 trial meets primary, secondary efficacy endpoints

A once daily oral liquid dose of up to 30mg ANAVEX2-73 (blarcamesine) demonstrated statistically significant and clinically meaningful reductions in symptoms with related changes in potential biomarkers (GABA and L-AAA) of disease pathology improvement over placebo, in adult women with Rett syndrome, according to top-line results from the Phase 3...

Read More
-Advertisement-
-Advertisement-
-Advertisement=-
-Advertisement-
-Advertisement-
-Advertisement=-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-